For accounting purposes, Biogen says its $223M inventory of Aduhelm is basically worthless

Submitted by admin on July 21, 2022 - 9:47pm

Source:

Endpoints

News Tags:

Biogen

Aduhelm

Alzheimer's disease

SEC

Headline:

For accounting purposes, Biogen says its $223M inventory of Aduhelm is basically worthless

snippet:

The battle over whether Biogen’s Alzheimer’s drug Aduhelm actually helps patients may never end, but in a recent SEC filing, Biogen, at least for accounting purposes, now says its $230 million stash of Aduhelm should be considered worthless.

Search form

You are here

For accounting purposes, Biogen says its $223M inventory of Aduhelm is basically worthless

For accounting purposes, Biogen says its $223M inventory of Aduhelm is basically worthless